<DOC>
	<DOCNO>NCT00528489</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , immune response DNA HIV vaccine , PENNVAX-B alone , combination IL-12 , 2 different dos IL-15 .</brief_summary>
	<brief_title>Safety Effectiveness PENNVAX-B Vaccine Alone , With Il-12 , IL-15 Healthy Adults</brief_title>
	<detailed_description>A vaccine effective multiple strain HIV remain best option prevent spread HIV . Plasmid DNA vaccine inexpensive easy construct . When DNA vaccine administer combination cytokine , IL-12 IL-15 , immune response vaccine increase . The purpose study determine safety tolerability DNA plasmid vaccine , PENNVAX-B administer alone , IL-12 IL-15 DNA adjuvant . The effective safe dose IL-15 also determine study . This study last approximately 12 month . Participants randomly assign one four group . Group 1 receive injection PENNVAX-B combine 0.8 mg IL-15 deltoid placebo . Group 2 receive injection PENNVAX-B alone placebo . Group 3 receive injection PENNVAX-B combine IL-12 deltoid placebo . Group 4 receive PENNVAX-B combine 2 mg IL-15 placebo . Injections occur study entry , Months 1 , 3 , 6 . Additional study visit occur Days 14 , 42 , 98 , 182 , 273 , 364 . At visit brief physical , blood collection , interview , risk reduction counsel occur . At visit HIV testing , urine collection , pregnancy test also occur . As 05/30/08 , participant enrol Groups 3 4 limited pace allow additional safety review first participant group . Additionally , safety data review Groups 1 2 determine whether remainder participant Groups 2 , 3 , 4 enrol .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>HIV1 2 uninfected Willing receive HIV test result Good general health Certain laboratory value within normal range site physician approval Negative Hepatitis B surface antigen Negative Hepatitis C test Willing use acceptable method contraception HIV vaccine placebos prior HIV trial . Participants provide documentation receive placebo prior HIV trial may eligible . Immunosuppressive medication within 168 day prior first study vaccination . Participants use corticosteroid nasal spray allergies topical corticosteroid mild , uncomplicated dermatitis exclude . Blood product within 120 day prior first study vaccination Receipt immunoglobulin within 60 day prior first vaccination Live attenuate vaccine within 30 day prior first study vaccination Any vaccine live attenuate vaccine within 14 day prior first study vaccination Investigational research agent within 60 day prior first study vaccination Current antituberculosis ( TB ) preventive therapy treatment clinically significant medical condition , abnormal physical exam finding , abnormal laboratory result , past medical history may affect current health . More information criterion find protocol . Any medical , psychiatric , social , occupational , condition responsibility opinion investigator would interfere study . More information criterion find protocol . Allergy amidetype local anesthetic Serious adverse reaction vaccine Autoimmune disease immunodeficiency Active syphilis infection . Participants fully treat syphilis 6 month prior study entry exclude . Asthma mild , wellcontrolled asthma . More information criterion find protocol . Type 1 type 2 diabetes mellitus . Participants history isolate gestational diabetes exclude . Thyroidectomy thyroid disease require medication 12 month prior study entry Accumulation fluid blood vessel ( angioedema ) within 3 year prior study entry episode consider serious require medication 2 year prior study entry Uncontrolled hypertension Body Mass Index 40 great OR 35 great certain criterion apply . More information criterion find protocol Bleeding disorder Cancer . Participants surgically remove cancer unlikely recur exclude . Seizure disorder Absence spleen Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>DNA Plasmid Vaccine</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>